DDX18 Antibody - #DF9258

Figure 2 DDX18 Upregulation in LUAD Tissues and its Functional Role in LUAD Cells. (a,b) Heatmaps depicting global mRNA expression profiles in GSE75037 [(a) non-tumor tissues (n = 83), LUAD tissues (n = 83)] and TCGA [(b) normal lung tissues (n = 287), LUAD tissues (n = 574)] datasets. DDX18 expression is indicated by the white line. (c,d) Boxplots representing DDX18 mRNA expression levels in non-tumor and LUAD tissues from GSE75037 (c) and TCGA (d) datasets. p-values are indicated. (e) Kaplan–Meier survival curve for overall survival of LUAD patients with high (n = 126) and low (n = 376) DDX18 expression. Low DDX18 expression correlates with improved overall survival (p-value indicated). (f) Relative DDX18 mRNA levels in H157 (n = 3) and H460 (n = 4) cells following DDX18 knockdown. Data represent mean ± SD. (g) Western blot analysis confirming DDX18 knockdown efficiency in H157 and H460 cells. (h) DDX18 knockdown significantly suppresses cell proliferation in H157 and H460 cells (n = 3, mean ± SD). (i) DDX18 knockdown substantially reduces colony formation capacity in H157 and H460 cells (n = 3, mean ± SD). (j) DDX18 knockdown inhibits the migration of H157 and H460 cells in vitro (n = 3, mean ± SD). ** p < 0.01; *** p < 0.001; **** p < 0.0001. LUAD, lung adenocarcinoma; SC, scramble control; KD, knockdown.